Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2006. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing reports a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs for Dr. R Greig on April 21, 2006, at a price of $53.01 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 21, 2006 (Notification date: April 25, 2006).
- Individual Involved: Dr. R Greig.
- Transaction Type: Increase in notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan.
- Share Price: $53.01 per share.
- Regulatory Basis: Notification required under Disclosure Rule 3.1.4R(1)(a).